Add-on therapy for pulmonary fibrosis, a forthcoming era with implications for practice: the BI 101550 and RELIEF trials

The therapeutic landscape for idiopathic pulmonary fibrosis (IPF) and progressive fibrosing interstitial lung disease (PFILD) is increasingly complex, with add-on antifibrotic options now in clinical trials, or available for patients progressing on first-line therapy in both conditions. Here, we rev...

Descripción completa

Detalles Bibliográficos
Autores principales: Planas-Cerezales, Lurdes, Fabbri, Laura, Pearmain, Laurence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2023
Materias:
Journal Club
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501707/
https://www.ncbi.nlm.nih.gov/pubmed/37719242
http://dx.doi.org/10.1183/20734735.0090-2023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501707/
https://www.ncbi.nlm.nih.gov/pubmed/37719242
http://dx.doi.org/10.1183/20734735.0090-2023

Ejemplares similares